Imap

Fluspirilene, the active ingredient in Imap, is a typical antipsychotic of the phenothiazine class presented as an intramuscular depot injection for intramuscular administration. It is indicated for the management of schizophrenia in adult patients, providing sustained dopamine D2 receptor blockade to help control psychotic symptoms.

GNH USA supplies Imap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled sourcing and regulatory compliance for global healthcare providers. The product meets EU market standards and is available for export.

Fluspirilene is a typical antipsychotic used in the treatment of schizophrenia, a disorder characterized by dopaminergic dysregulation. - Schizophrenia: Reduces positive and negative symptoms and helps prevent relapse. - Maintenance therapy in schizophrenia: Provides long‑acting dopamine blockade to improve adherence. - Acute exacerbation of schizophrenia: Offers rapid symptom control when oral therapy is insufficient.

Common Side Effects: - Sedation: Drowsiness or reduced alertness. - Extrapyramidal symptoms: Tremor, rigidity, or akathisia. - Dry mouth: Reduced salivation. - Constipation: Decreased bowel motility. - Orthostatic hypotension: Light‑headedness on standing. - Weight gain: Increased appetite and body weight.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: Life‑threatening hyperthermia and muscle rigidity. - Tardive dyskinesia: Persistent involuntary movements. - Severe hypotension: Marked drop in blood pressure. - Seizures: Increased risk of convulsive episodes. - Agranulocytosis: Dangerous reduction in white blood cells. - Cardiac arrhythmia: Irregular heart rhythm, including QT prolongation.

Fluspirilene should be used with caution in specific clinical situations. - Pregnancy: Use only if potential benefit justifies the risk to the fetus. - Breastfeeding: Not recommended unless essential, due to possible infant exposure. - Elderly patients: Monitor for orthostatic hypotension and enhanced sedation. - Cardiovascular disease: Observe blood pressure and perform ECG monitoring. - Concomitant CNS depressants: Caution for additive sedative effects. - Store at controlled room temperature: Keep in the original packaging, protect from light and moisture.

Fluspirilene may interact with several medicines; clinical monitoring is advised. Major Interactions (Avoid): - CYP2D6 inhibitors: May increase fluspirilene plasma concentrations. - Other antipsychotics: Heightened risk of extrapyramidal symptoms. - Antihypertensives: Additive hypotensive effect. - QT‑prolonging drugs: Increased risk of cardiac arrhythmia. Moderate Interactions (Monitor Closely): - Anticholinergic agents: May mask anticholinergic side effects. - CNS depressants (alcohol, benzodiazepines): Enhanced sedation. - Lithium: Potential increase in neurotoxicity.